Novartis’ Fabhalta Demonstrates Significant Proteinuria Reduction In IgA Nephropathy Patients
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Novartis (NVS) presented results from a pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta (iptacopan), an investigational Factor B inhibitor of the alternative complement pathway, in patients with IgA nephropathy or IgAN. Results were pre
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-80864706-af4bc38e94e34052a5106e15bf44b2a2.jpg "Benchmark Oils: Brent Crude, WTI, and Dubai")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-77294443-88c7023010c9410c933c8029b3931c91.jpg "Reasons to Avoid Long-Term Auto Loans")